Press Releases

Press Releases

Proposed Phase 2 Study to Take Place in New York City Under U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP) SOUTH SAN FRANCISCO, Calif., April 28, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines
SOUTH SAN FRANCISCO, Calif., March 25, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and central nervous system (CNS) diseases and disorders with high unmet medical need, today
PH10, a Neurosteroid Nasal Spray, Demonstrated Significant Rapid-Onset Antidepressive Benefit versus Placebo, without Psychological Side Effects or Safety Concerns Often Associated with Ketamine-based Therapy SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 /PRNewswire/ --  VistaGen Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced financial results for
When given together with VistaGen's oral prodrug AV-101, probenecid increased brain concentrations of AV-101 7-fold and its active metabolite, 7-CI-KYNA, 35-fold SOUTH SAN FRANCISCO, Calif., Feb. 11, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical
Company also Receives a Notice of Allowance from the USPTO for a New AV-101 U.S. Patent for Treatment of Dyskinesia Induced by Levodopa Therapy SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing
Multiple electrophysiological biomarkers indicate AV-101's NMDA receptor target engagement Both AV-101 doses were well-tolerated and not associated with dissociative or serious adverse events Poster presented at 2019 Annual Meeting of American College of Neuropsychopharmacology SOUTH SAN FRANCISCO,
VistaGen's PH94B is the first drug candidate to be granted U.S. FDA Fast Track designation for treatment of social anxiety disorder SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 /PRNewswire/ --  VistaGen Therapeutics, Inc.  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced topline results from the
SOUTH SAN FRANCISCO, Calif., Nov. 7, 2019 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced financial results for its
Displaying 61 - 70 of 194